Microbiome–Gut–Brain Axis Modulation: New Approaches in Treatment of Neuropsychological and Gastrointestinal Functional Disorders

The gut-brain axis (GBA) is a bidirectional communication system linking the digestive system and the central nervous system through neuro-immune and hormonal pathways. The gut microbiome plays a key role in this communication, influencing mental health. This Patent Highlight describes methods to promote colonization of spore-forming bacteria in the gastrointestinal tract by administering serotonin receptor agonists, including psychedelic compounds such as psilocybin, psilocin, N,N-dimethyltryptamine, bufotenine, 5-methoxy-N,N-dimethyltryptamine, lysergic acid diethylamide, ergine, mescaline, 3,4-methylenedioxyamphetamine, and 2,5-dimethoxy-4-methylamphetamine.

Study at a glance

Abstract

The gut-brain axis (GBA) refers to the sophisticated bidirectional communication system connecting the digestive system with the central nervous system. This interaction is enabled by a series of intricate signaling processes, encompassing various neuro-immune and hormonal pathways. The association between the gut microbiome and mental health has garnered immense scientific and public interest, driven by an enhanced understanding of the microbiome's role in facilitating communication between the gut and the brain. This Patent Highlight discloses methods for promoting the colonization of spore-forming bacteria in the gastrointestinal track. These methods include administering a serotonin receptor agonist, such as psilocybin, psilocin, N,N-dimethyltryptamine, bufotenine, 5-methoxy-N,N-dimethyltryptamine, lysergic acid diethylamide, ergine, mescaline, 3,4-methylenedioxyamphetamine, 2,5-dimethoxy-4-methylamphetamine, and others.